Pfizer Blames Patent Expirations For Weaker Profit Outlook
Patent expirations continue to weigh on the profitability of Pfizer Inc., the drug maker's chief executive told analysts on Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article